Pubblicazioni

Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly

2022 - ENDOCRINE
Chiloiro, Sabrina; Costa, Denise; Lauretta, Rosa; Mercuri, Valeria; Sbardella, Emilia; Samperi, Irene; Appetecchia, Marialuisa; Bianchi, Antonio; Giampietro, Antonella; Gargiulo, Patrizia; Isidori, Andrea M; Poggi, Maurizio; Pontecorvi, Alfredo; De Marinis, Laura

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

2019 - ENDOCRINE
Pivonello, R.; Arnaldi, G.; Scaroni, C.; Giordano, C.; Cannavo, S.; Iacuaniello, D.; Trementino, L.; Zilio, M.; Guarnotta, V.; Albani, A.; Cozzolino, A.; Michetti, G.; Boscaro, M.; Colao, A.

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study

2018 - ENDOCRINE
Faggiano, Antongiulio; Modica, Roberta; Severino, Rosa; Camera, Luigi; Fonti, Rosa; Del Prete, Michela; Chiofalo, Maria Grazia; Aria, Massimo; Ferolla, Piero; Vitale, Giovanni; Pezzullo, Luciano; Colao, Annamaria

The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center

2015 - ENDOCRINE
Simeoli, Chiara; Auriemma, Renata Simona; Tortora, Fabio; De Leo, Monica; Iacuaniello, Davide; Cozzolino, Alessia; De Martino, Maria Cristina; Pivonello, Claudia; Mainolfi, Ciro Gabriele; Rossi, Riccardo; Cirillo, Sossio; Colao, Annamaria; Pivonello, Rosario

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma